A Breakthrough in Autoimmune Therapy

ELDYENN is a biotechnology start-up focused on using Low Dose Naltrexone (LDN) for the treatment of autoimmune diseases.


Our research is backed by Dr. Jill Smith, a leading expert in the field.


Low dose naltrexone (LDN) has few side effects, most of which are minor.


Clinically proven to reduce inflammation and disease flares.

Eldyenn will revolutionize how autoimmune diseases are managed, focusing on developing immunomodulatory – rather than immunosuppressive – drugs. We’re starting our journey with Low Dose Naltrexone (LDN).

About us

Our Mission: Transform Lives

We are a biotech startup dedicated to finding innovative solutions for treating autoimmune diseases, starting with pediatric Crohn’s Disease. Drug therapies currently available for Crohn’s Disease often have major side-effects, which can be especially problematic for children. By leveraging Low Dose Naltrexone (LDN), our company aims to provide a safer option that can strategically target the specific areas of the immune system that are causing the disease.

Our team of experts is committed to conducting rigorous clinical trials, collaborating with leading physicians and researchers in the field, and working closely with patients and families affected by Autoimmune Conditions. We believe in a holistic approach to healthcare that puts the patient at the center of treatment, and our startup is dedicated to creating safe and effective solutions that improve patients’ quality of life.

We’re excited to be at the forefront of innovation in the biotech industry and are committed to finding new ways of battling autoimmune diseases. Our mission is to give patients a new level of hope, and with our cutting-edge research and development, we are confident that we can make a real difference for those living with Crohn’s Disease and related autoimmune disorders.

Dr. Stephen Wilson, CEO

Dad with child is sitting on the bench in the corridor of hospital
Low Dose Naltrexone (LDN)

Focusing on Immunomodulation

LDN works by regulating the immune system, unlike other drugs that suppress it. Furthermore, it has minimal side effects and can be administered orally, making it more convenient for patients. LDN could redefine the treatment pathways for autoimmune conditions and provide a much-needed solution for patients who are currently struggling to manage their symptoms.

Healthcare, trust and medical consulting with doctor and child at hospital, exam with stethoscope.
Our Pipeline

Restoring Hope

Improving outcomes while reducing the negative side effects of immunosuppressive therapy. 

0 %
Showed Improvement
0 %
Achieved Remission
Adverse Events
Our Data

Promising Phase 2 Results

Low dose naltrexone (LDN) is showing promise as a potential treatment for Pediatric Crohn’s Disease in our recent phase 2 clinical trial results. The trial, which involved 12 children and adolescents with moderately severe Crohn’s Disease, showed that after 8 weeks of LDN treatment, patients experienced a significant reduction in disease activity and improved quality of life.

LDN works by blocking the body’s natural opioids, which helps to regulate the immune system and reduce inflammation. Unlike conventional medication, LDN does not come with a long list of side effects, making it an attractive alternative for patients who cannot tolerate or do not respond to other treatments. These results are encouraging and offer hope for those affected by Pediatric Crohn’s Disease.